Too many targets, not enough patients: rethinking neuroblastoma clinical trials.

Abstract excerpt

Neuroblastoma is a rare solid tumour of infancy and early childhood with a disproportionate contribution to paediatric cancer mortality and morbidity. Combination chemotherapy, radiation therapy and immunotherapy remains the standard approach to treat high-risk disease, with few recurrent, actionable genetic aberrations identified at diagnosis. However, recent studies indicate that actionable aberrations are far...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anaplastic Lymphoma Kinase
• Share to Antineoplastic Agents, Immunological